Danny Lee has been appointed to the board of the regenerative medical devices company “with immediate effect”.
Before joining Tissue Regenix last January, he was CEO for Scaffold Biologics and Aperion Biologics.
He will succeed Gareth Jones, formerly chief financial officer, who was made interim CEO last August. While he is stepping down from the board, Jones is staying with the company until the end of the year to ensure an “orderly handover”.
“I would like to thank Gareth for his leadership during a transitional period for the company,” said Lee.
“I am honoured to be selected to lead this company. Throughout my career, I have been passionate about building and growing companies in the regenerative medical space.
“During my tenure at the company, I have had the opportunity to appreciate the impact created by our proprietary products and the exceptional capabilities of our team.”